Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Heterogeneity of treatment effect

9 evidence topics · 7 sources

BOND-003 Cohort C: tumor pattern and prior therapy at study entry
Baseline characteristicn%
CIS with high-grade Ta/T1“22”“19.6”
CIS alone“90”“80.4”
At least one prior therapy other than BCG“53”“47.3”
Serial adjuvant chemotherapy“34”“30.4”
Systemic immunotherapy“7”“6.3”